Skip to main content

Table 3 Factors related to GSM treatment adherence during COVID-19 confinement

From: Women's knowledge about the genitourinary syndrome of menopause: adherence to its treatments in the COVID-19 era in a sample of them: COMEM-GSM study

 

Good compliancea (n = 56)

Poor complianceb (n = 148)

p value

Age

   

Median (RIQ*)

58 (53.7–60.2)

59 (54–60)

0.988

Years of menopause

   

Median (RIQ)

50 (49–52)

50 (49–52)

0.693

Sexually active before confinement

   

Yes

48 (85.7)

128 (86.5)

0.919

No

8 (14.3)

20 (13.5)

 

Level of education

   

Basic-medium

28 (50)

84 (56.8)

0.541

Higher

28 (50)

64 (43.2)

 

Decreased sexual activity

   

Yes

12 (21.4)

100 (67.6)

< 0.001

No

44 (78.6)

48 (32.4)

 

Indicated treatments

   

Lubricants, moisturizers

12 (21.4)

36 (24.3)

0.218

Local estrogens

32 (57.1)

88 (59.5)

 

Prasterone

4 (7.1)

16 (10.8)

 

Ospemifene

8 (14.3)

4 (2.7)

 

MHT

-

4 (2,7)

 

COVID infection

   

Yes

16 (28.6)

8 (5.4)

0.003

No

40 (71.4)

140 (94.6)

 
  1. MTH menopause hormone therapy
  2. *RIQ: Interquartile range
  3. aCompliance was considered to be good if the 4 questions of the Morinsky–Green–Levine test were answered correctly, as follows: No/Yes/No/No [8]
  4. bCompliance was considered to be poor if any of these 4 questions were answered incorrectly